Made for Selectivity
Made for Remission
Made for Now
Entyvio works through a gut-selective MOA by specifically binding to the α4β7 integrin and blocking its interaction with MAdCAM-1, which is mainly expressed on gut endothelial cells.1-7
Remission was evaluated at Week 52.1 Individual results may vary.
For adult patients with moderately to severely active UC or CD when other therapies have not worked well enough or cannot be tolerated.
The #1 prescribed biologic for bio-naïve UC and CD patients*
*Based on a month to month analysis of Symphony medical and pharmacy claims from July 2020 to August 2022 with “bio-naïve” defined as patients with UC or CD who had no biologic claims in the past 3 years. Biologics include Cimzia® (certolizumab pegol; UCB, Inc., Smyrna, GA), Humira® (adalimumab; AbbVie Inc., North Chicago, IL), Remicade® (infliximab; Janssen Biotech, Inc., Horsham, PA), Stelara® (ustekinumab; Janssen Biotech, Inc., Horsham, PA), Simponi® (golimumab; Janssen Biotech, Inc., Horsham, PA), and infliximab bio-similars. December 2022.
Entyvio (vedolizumab) Combines
Gut Selectivity2-7
Entyvio helps address inflammation where it occurs—the gut.1
Entyvio specifically binds to the α4β7 integrin and blocks the interaction between the α4β7 integrin and MAdCAM-1, which is mainly expressed on the GI tract endothelial cells.
Clinical trials evaluated safety in more than 3300 adults (UC, CD, and healthy volunteers).1 A separate open-label study of up to 7 years demonstrated consistent results across safety parameters.1,10,11†
†In a single-arm, open-label extension study of 2243 patients who received Entyvio with a median exposure of 1072 days (range 1 to 3412 days).10,11
§This information is derived from a Symphony database of Entyvio medical and pharmacy claims from June 2014 to preliminary August 2022. October 2022.
||First-line/unrestricted refers to coverage that does not require biologic step-edits. Data regarding current first-line/unrestricted commercial coverage for Entyvio as of September 2022 and derived from Managed Markets Insights & Technology (MMIT). October 2022
Sands BE, Sandborn WJ, Van Assche G, et al. Inflamm Bowel Dis. 2017;23(1):97-106.
Loftus EV, Feagan BG, Panaccione R, et al; for the GEMINI LTS study team. Aliment Pharmacol Ther. 2020;00:1-13.
Data on File. Takeda Pharmaceuticals.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. N Engl J Med. 2019;381(13):1215-1226.
Macaluso FS, Maida M, Grova M, et al. Therap Adv Gastroenterol. 2021;14:1-11.
You are about to leave this website.
By clicking "Continue," you will leave this site and enter TakedaMedConnect.com. The information contained on Takeda MedConnect is intended for U.S. healthcare professionals only in response to a specific request for medical information.
You are about to leave this website.
You are about to leave this website and enter a website operated by an independent third party.
The links to third-party websites contained on this website are provided solely for your convenience. Takeda does not control the content contained on any third-party website linked from this website. Your activities at those websites will be governed by the policies and practices of those third parties.
Please select "Continue" if you wish to be taken to this third-party website.